Fenfluramine is a serotonergic antiseizure agent used in Dravet syndrome. The clinically decisive safety issue is rooted in its serotonin pharmacology.
Serotonergic stimulation of $5\text{-}HT_{2B}$ receptors on cardiac valves drives fibrotic valvular thickening and can raise pulmonary vascular pressure. This is the same mechanism that caused the notorious fen-phen valvular heart disease in the 1990s. Consequently, regulatory labelling requires cardiac surveillance: an echocardiogram before starting, repeated during treatment, and after stopping, to screen for valvular regurgitation and pulmonary arterial hypertension.
The other options belong to different drugs - agranulocytosis to clozapine/carbamazepine, hepatic failure to valproate/felbamate, and renal failure is not the signature fenfluramine toxicity. Therefore cardiovascular (echo) monitoring is the answer.
\[\boxed{\text{Monitor cardiovascular status with echocardiography}}\]